Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The rel...
Saved in:
| Main Authors: | Amir Khammari, Anne-Chantal Knol, Jean-Michel Nguyen, Céline Bossard, Marc-Guillaume Denis, Marie-Christine Pandolfino, Gaëlle Quéreux, Sylvain Bercegeay, Brigitte Dréno |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/186212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial
by: Jean-Matthieu L'Orphelin, et al.
Published: (2024-11-01) -
Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
by: S. Dalle, et al.
Published: (2024-01-01) -
Adjuvant Therapy: Melanoma
by: Diwakar Davar, et al.
Published: (2011-01-01) -
An update on adjuvant systemic therapies in melanoma
by: Evangeline Samuel, et al.
Published: (2019-11-01) -
Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study
by: Lucille Vitek, et al.
Published: (2024-12-01)